Literature DB >> 12438345

T-cell responses to the Mycobacterium tuberculosis-specific antigen ESAT-6 in Brazilian tuberculosis patients.

Fernando L L Cardoso1, Paulo R Z Antas, Alexandre S Milagres, Annemieke Geluk, Kees L M C Franken, Eliane B Oliveira, Henrique C Teixeira, Susie A Nogueira, Euzenir N Sarno, Paul Klatser, Tom H M Ottenhoff, Elizabeth P Sampaio.   

Abstract

The Mycobacterium tuberculosis-specific ESAT-6 antigen induces highly potent T-cell responses and production of gamma interferon (IFN-gamma), which play a critical role in protective cell-mediated immunity against tuberculosis (TB). In the present study, IFN-gamma secretion by peripheral blood mononuclear cells (PBMCs) in response to M. tuberculosis ESAT-6 in Brazilian TB patients was investigated in relation to clinical disease types, such as pleurisy and cavitary pulmonary TB. Leprosy patients, patients with pulmonary diseases other than TB, and healthy donors were assayed as control groups. Sixty percent of the TB patients indeed recognized M. tuberculosis ESAT-6, as did 50% of the leprosy patients and 60% of the non-TB controls. Nevertheless, the levels of IFN-gamma in response to the antigen ESAT, but not to antigen 85B (Ag85B) and purified protein derivative (PPD), were significantly lower in controls than in patients with treated TB or pleural or cavitary TB. Moreover, according to Mycobacterium bovis BCG vaccination status, only 59% of the vaccinated TB patients responded to ESAT in vitro, whereas 100% of them responded to PPD. Both CD4 and CD8 T cells were able to release IFN-gamma in response to ESAT. The present data demonstrate the specificity of ESAT-6 of M. tuberculosis and its ability to discriminate TB patients from controls, including leprosy patients. However, to obtain specificity, it is necessary to include quantitative IFN-gamma production in response to the antigen as well, and this might limit the use of ESAT-6-based immunodiagnosis of M. tuberculosis infection in an area of TB endemicity.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12438345      PMCID: PMC132944          DOI: 10.1128/IAI.70.12.6707-6714.2002

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  44 in total

1.  Detection of active tuberculosis infection by T cell responses to early-secreted antigenic target 6-kDa protein and culture filtrate protein 10.

Authors:  S M Arend; P Andersen; K E van Meijgaarden; R L Skjot; Y W Subronto; J T van Dissel; T H Ottenhoff
Journal:  J Infect Dis       Date:  2000-05-15       Impact factor: 5.226

2.  Purification of his-tagged proteins by immobilized chelate affinity chromatography: the benefits from the use of organic solvent.

Authors:  K L Franken; H S Hiemstra; K E van Meijgaarden; Y Subronto; J den Hartigh; T H Ottenhoff; J W Drijfhout
Journal:  Protein Expr Purif       Date:  2000-02       Impact factor: 1.650

3.  Multiple epitopes from the Mycobacterium tuberculosis ESAT-6 antigen are recognized by antigen-specific human T cell lines.

Authors:  A S Mustafa; F Oftung; H A Amoudy; N M Madi; A T Abal; F Shaban; I Rosen Krands; P Andersen
Journal:  Clin Infect Dis       Date:  2000-06       Impact factor: 9.079

4.  Fifteen year follow up of trial of BCG vaccines in south India for tuberculosis prevention. Tuberculosis Research Centre (ICMR), Chennai.

Authors: 
Journal:  Indian J Med Res       Date:  1999-08       Impact factor: 2.375

5.  Tuberculosis contacts but not patients have higher gamma interferon responses to ESAT-6 than do community controls in The Gambia.

Authors:  J Vekemans; C Lienhardt; J S Sillah; J G Wheeler; G P Lahai; M T Doherty; T Corrah; P Andersen; K P McAdam; A Marchant
Journal:  Infect Immun       Date:  2001-10       Impact factor: 3.441

Review 6.  Variation in protection by BCG: implications of and for heterologous immunity.

Authors:  P E Fine
Journal:  Lancet       Date:  1995-11-18       Impact factor: 79.321

7.  Antigenic specificity of the Mycobacterium leprae homologue of ESAT-6.

Authors:  John S Spencer; Maria Angela M Marques; Monica C B S Lima; Ana Paula Junqueira-Kipnis; Bruce C Gregory; Richard W Truman; Patrick J Brennan
Journal:  Infect Immun       Date:  2002-02       Impact factor: 3.441

8.  Enumeration of T cells specific for RD1-encoded antigens suggests a high prevalence of latent Mycobacterium tuberculosis infection in healthy urban Indians.

Authors:  A Lalvani; P Nagvenkar; Z Udwadia; A A Pathan; K A Wilkinson; J S Shastri; K Ewer; A V Hill; A Mehta; C Rodrigues
Journal:  J Infect Dis       Date:  2000-12-21       Impact factor: 5.226

9.  Human CD8(+) T cells specific for Mycobacterium tuberculosis secreted antigens in tuberculosis patients and healthy BCG-vaccinated controls in The Gambia.

Authors:  S M Smith; M R Klein; A S Malin; J Sillah; K Huygen; P Andersen; K P McAdam; H M Dockrell
Journal:  Infect Immun       Date:  2000-12       Impact factor: 3.441

10.  Identification of major epitopes of Mycobacterium tuberculosis AG85B that are recognized by HLA-A*0201-restricted CD8+ T cells in HLA-transgenic mice and humans.

Authors:  A Geluk; K E van Meijgaarden; K L Franken; J W Drijfhout; S D'Souza; A Necker; K Huygen; T H Ottenhoff
Journal:  J Immunol       Date:  2000-12-01       Impact factor: 5.422

View more
  18 in total

1.  Are cultures needed to enroll tuberculosis patients?

Authors:  Mihai-Sergiu Jalba
Journal:  Infect Immun       Date:  2003-12       Impact factor: 3.441

2.  Sensitivity analysis and potential uses of a novel gamma interferon release assay for diagnosis of tuberculosis.

Authors:  Simon J Tsiouris; David Coetzee; Patricia L Toro; Judy Austin; Zena Stein; Wafaa El-Sadr
Journal:  J Clin Microbiol       Date:  2006-08       Impact factor: 5.948

3.  Detection of in vitro interferon-gamma and serum tumour necrosis factor-alpha in multidrug-resistant tuberculosis patients.

Authors:  A Fortes; K Pereira; P R Z Antas; C L M C Franken; M Dalcolmo; M M Ribeiro-Carvalho; K S Cunha; A Geluk; A Kritski; A Kolk; P Klatser; E N Sarno; T H M Ottenhoff; E P Sampaio
Journal:  Clin Exp Immunol       Date:  2005-09       Impact factor: 4.330

4.  Unique model of dormant infection for tuberculosis vaccine development.

Authors:  Suely S Kashino; Pamela Ovendale; Angelo Izzo; Antonio Campos-Neto
Journal:  Clin Vaccine Immunol       Date:  2006-09

5.  More significance of TB-IGRA except for the diagnose of tuberculosis.

Authors:  Jun-Chi Xu; Ze-Yi Li; Xin-Nian Chen; Cui-Lin Shi; Mei-Ying Wu; Hui Chen; Xiao-Yan Zhu; Hua-Feng Song; Min-Juan Wu; Ping Xu
Journal:  J Clin Lab Anal       Date:  2017-02-21       Impact factor: 2.352

6.  Rv0315, a novel immunostimulatory antigen of Mycobacterium tuberculosis, activates dendritic cells and drives Th1 immune responses.

Authors:  Eui-Hong Byun; Woo Sik Kim; A-Rum Shin; Jong-Seok Kim; Jake Whang; Choul-Jae Won; Yohan Choi; Su-Young Kim; Won Jung Koh; Hwa-Jung Kim; Sung Jae Shin
Journal:  J Mol Med (Berl)       Date:  2011-10-13       Impact factor: 4.599

7.  Blood Cells and Interferon-Gamma Levels Correlation in Latent Tuberculosis Infection.

Authors:  Iukary Takenami; Camila Loureiro; Almério Machado; Krisztina Emodi; Lee W Riley; Sérgio Arruda
Journal:  ISRN Pulmonol       Date:  2013

8.  Identification of early secretory antigen target-6 epitopes for the immunodiagnosis of active tuberculosis.

Authors:  Donatella Vincenti; Stefania Carrara; Patrizia De Mori; Leopoldo P Pucillo; Nicola Petrosillo; Fabrizio Palmieri; Orlando Armignacco; Giuseppe Ippolito; Enrico Girardi; Massimo Amicosante; Delia Goletti
Journal:  Mol Med       Date:  2003 Mar-Apr       Impact factor: 6.354

9.  Evaluation of T-cell responses to novel RD1- and RD2-encoded Mycobacterium tuberculosis gene products for specific detection of human tuberculosis infection.

Authors:  Xiao-Qing Liu; Davinder Dosanjh; Hansa Varia; Katie Ewer; Paul Cockle; Geoffrey Pasvol; Ajit Lalvani
Journal:  Infect Immun       Date:  2004-05       Impact factor: 3.441

10.  Mycobacterial antigen-induced T helper type 1 (Th1) and Th2 reactivity of peripheral blood mononuclear cells from diabetic and non-diabetic tuberculosis patients and Mycobacterium bovis bacilli Calmette-Guérin (BCG)-vaccinated healthy subjects.

Authors:  R J Al-Attiyah; A S Mustafa
Journal:  Clin Exp Immunol       Date:  2009-10       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.